204 related articles for article (PubMed ID: 9521254)
1. Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease.
Farlow MR; Lahiri DK; Poirier J; Davignon J; Schneider L; Hui SL
Neurology; 1998 Mar; 50(3):669-77. PubMed ID: 9521254
[TBL] [Abstract][Full Text] [Related]
2. Apolipoprotein E genotype and gender influence response to tacrine therapy.
Farlow MR; Lahiri DK; Poirier J; Davignon J; Hui S
Ann N Y Acad Sci; 1996 Dec; 802():101-10. PubMed ID: 8993489
[TBL] [Abstract][Full Text] [Related]
3. The apolipoprotein E epsilon4 allele and the response to tacrine therapy in Alzheimer's disease.
Rigaud AS; Traykov L; Caputo L; Guelfi MC; Latour F; Couderc R; Moulin F; de Rotrou J; Forette F; Boller F
Eur J Neurol; 2000 May; 7(3):255-8. PubMed ID: 10886308
[TBL] [Abstract][Full Text] [Related]
4. Responder characteristics to a single oral dose of cholinesterase inhibitor: a double-blind placebo-controlled study with tacrine in Alzheimer patients.
Almkvist O; Jelic V; Amberla K; Hellström-Lindahl E; Meurling L; Nordberg A
Dement Geriatr Cogn Disord; 2001; 12(1):22-32. PubMed ID: 11125238
[TBL] [Abstract][Full Text] [Related]
5. Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer's disease.
Schneider LS; Farlow MR; Henderson VW; Pogoda JM
Neurology; 1996 Jun; 46(6):1580-4. PubMed ID: 8649552
[TBL] [Abstract][Full Text] [Related]
6. Combined tacrine and estrogen replacement therapy in patients with Alzheimer's disease.
Schneider LS; Farlow M
Ann N Y Acad Sci; 1997 Sep; 826():317-22. PubMed ID: 9329702
[TBL] [Abstract][Full Text] [Related]
7. Tacrine and rate of progression in Alzheimer's disease--relation to ApoE allele genotype.
Sjögren M; Hesse C; Basun H; Köl G; Thostrup H; Kilander L; Marcusson J; Edman A; Wallin A; Karlsson I; Troell M; Wachtmaister G; Ekdahl A; Olofsson H; Sandström A; Andreasen N; Minthon L; Blennow K
J Neural Transm (Vienna); 2001; 108(4):451-8. PubMed ID: 11475012
[TBL] [Abstract][Full Text] [Related]
8. Potential role for estrogen replacement in the treatment of Alzheimer's dementia.
Schneider LS; Farlow MR; Pogoda JM
Am J Med; 1997 Sep; 103(3A):46S-50S. PubMed ID: 9344406
[TBL] [Abstract][Full Text] [Related]
9. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group.
Knapp MJ; Knopman DS; Solomon PR; Pendlebury WW; Davis CS; Gracon SI
JAMA; 1994 Apr; 271(13):985-91. PubMed ID: 8139083
[TBL] [Abstract][Full Text] [Related]
10. Cerebral glucose metabolism, cerebrospinal fluid-beta-amyloid1-42 (CSF-Abeta42), tau and apolipoprotein E genotype in long-term rivastigmine and tacrine treated Alzheimer disease (AD) patients.
Stefanova E; Blennow K; Almkvist O; Hellström-Lindahl E; Nordberg A
Neurosci Lett; 2003 Feb; 338(2):159-63. PubMed ID: 12566177
[TBL] [Abstract][Full Text] [Related]
11. Apolipoprotein E epsilon4 allele differentiates the clinical response to donepezil in Alzheimer's disease.
Bizzarro A; Marra C; Acciarri A; Valenza A; Tiziano FD; Brahe C; Masullo C
Dement Geriatr Cogn Disord; 2005; 20(4):254-61. PubMed ID: 16103669
[TBL] [Abstract][Full Text] [Related]
12. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group.
Davis KL; Thal LJ; Gamzu ER; Davis CS; Woolson RF; Gracon SI; Drachman DA; Schneider LS; Whitehouse PJ; Hoover TM
N Engl J Med; 1992 Oct; 327(18):1253-9. PubMed ID: 1406817
[TBL] [Abstract][Full Text] [Related]
13. An enriched-population, double-blind, placebo-controlled, crossover study of tacrine and lecithin in Alzheimer's disease. The Tacrine 970-6 Study Group.
Foster NL; Petersen RC; Gracon SI; Lewis K
Dementia; 1996; 7(5):260-6. PubMed ID: 8872417
[TBL] [Abstract][Full Text] [Related]
14. Effect of gender and apolipoprotein E genotype on response to anticholinesterase therapy in Alzheimer's disease.
MacGowan SH; Wilcock GK; Scott M
Int J Geriatr Psychiatry; 1998 Sep; 13(9):625-30. PubMed ID: 9777427
[TBL] [Abstract][Full Text] [Related]
15. Hormone replacement therapy in postmenopausal women with Alzheimer's disease: a randomized, prospective study.
Yoon BK; Kim DK; Kang Y; Kim JW; Shin MH; Na DL
Fertil Steril; 2003 Feb; 79(2):274-80. PubMed ID: 12568834
[TBL] [Abstract][Full Text] [Related]
16. Metrifonate treatment of AD: influence of APOE genotype.
Farlow MR; Cyrus PA; Nadel A; Lahiri DK; Brashear A; Gulanski B
Neurology; 1999 Dec; 53(9):2010-6. PubMed ID: 10599773
[TBL] [Abstract][Full Text] [Related]
17. Effect of the apolipoprotein E epsilon4 allele on the efficacy and tolerability of galantamine in the treatment of Alzheimer's disease.
Suh GH; Jung HY; Lee CU; Oh BH; Lee SK; Lee N; Kim J; Kee BS; Ko D; Kim YH; Ju YS; Hong I; Choi S;
Dement Geriatr Cogn Disord; 2006; 21(1):33-9. PubMed ID: 16254428
[TBL] [Abstract][Full Text] [Related]
18. Cholesterol and APOE genotype interact to influence Alzheimer disease progression.
Evans RM; Hui S; Perkins A; Lahiri DK; Poirier J; Farlow MR
Neurology; 2004 May; 62(10):1869-71. PubMed ID: 15159498
[TBL] [Abstract][Full Text] [Related]
19. Presence or absence of at least one epsilon 4 allele and gender are not predictive for the response to donepezil treatment in Alzheimer's disease.
Rigaud AS; Traykov L; Latour F; Couderc R; Moulin F; Forette F
Pharmacogenetics; 2002 Jul; 12(5):415-20. PubMed ID: 12142731
[TBL] [Abstract][Full Text] [Related]
20. Cholinesterase inhibition for Alzheimer disease: a meta-analysis of the tacrine trials. Dementia Trialists' Collaboration.
Qizilbash N; Whitehead A; Higgins J; Wilcock G; Schneider L; Farlow M
JAMA; 1998 Nov; 280(20):1777-82. PubMed ID: 9842955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
